雷贝拉唑、莫沙必利与玄麦甘桔三联用药治疗咽喉反流疾病的临床疗效

Clinical Efficacy of Combined Medication with Rebeprazole, Mosapride and Xuanmaiganjie in the Treatment of Pharyngeal and Laryngeal Reflux Disease

目的 :研究雷贝拉唑、莫沙必利与玄麦甘桔三联用药治疗咽喉反流疾病(PLRD)的效果及对反流症状的改善情况。方法 :选取2015年6月-2016年12月在我院治疗的90例PLRD患者,按随机数字表法分为三组:A组、B组、C组,各30例。A组患者口服雷贝拉唑(20 mg,qd)治疗,B组口服雷贝拉唑(20 mg,qd)和莫沙必利(5 mg,tid)治疗,C组在B组基础上加服玄麦甘桔颗粒(5 mg,tid)治疗,比较三组临床疗效、反流症状指数量表(RFS)评分、反流检查体征量表(RSI)评分及反流症状缓解时间。结果 :C组治疗总有效率为90.0%,均明显高于A组的56.7%、B组的73.3%,差异有统计学意义(P<0.05);治疗后三组RFS评分、RSI评分均下降,但C组下降最显著,差异有统计学意义(P<0.05);治疗后C组反复清嗓、发生障碍及咽部异物感缓解所需时间,均明显比A组、B组所需时间短,差异有统计学意义(P<0.05)。结论:雷贝拉唑、莫沙必利与玄麦甘桔联合治疗LPRD效果较好,可明显改善反流症状,促进患者早日恢复健康,改善预后,提高生活质量,值得临床上广泛推广应用。

Objective:To study the effect of rebeprazole, mosapride and xuanmaiganjie in the treatment of pharyngeal and laryngeal reflux disease(PLRD) and the improvement of reflux symptoms. Methods:90 PLRD patients treated in otolaryngology department of Central Hospital of Xinxiang City from June 2015 to December 2016 were randomly divided into three groups: group A, group B and group C, with 30 patients in each group. Patients in group A were treated with oral rabeprazole(20 mg, qd), patients in group B were treated with rabeprazole(20 mg, qd) and mosapride(5 g, tid), and patients in group C were additionally treated with xuanmaiganjie granules(5 g, tid)besides the treatment in group B. The clinical efficacy, reflux symptom index scale(RFS) score, reflux check sign scale(RSI) score and time required for symptom remission in the three groups were compared. Results:The total effective rate of group C was 90.0%, which was significantly higher than those of group A(56.7%) and group B(73.3%, P<0.05). The scores of RFS and RSI were decreased in all the three groups after treatment. The most sharp change was observed in group C, and the difference was statistically significant(P<0.05).The time required for the relief of symptoms like throat-clearing repeatedly, occurrence obstacle and foreign body sensation in the pharynx in group C was significantly shorter than those in group A and group B(P<0.05). Conclusion:Combined medication with rebeprazole, mosapride and xuanmaiganjie granules shows superior efficacy in the treatment of PLRD, which can significantly improve the symptoms of reflux, promote the recovery, and improve the prognosis and life quality, it is worth widely popularization and application in clinical practice.